Long-term drug treatment of benign prostatic hyperplasia — results of a prospective 3-year multicenter study using Sabal extract IDS 89

Phytomedicine - Tập 3 - Trang 105-111 - 1996
D. Bach1, L. Ebeling2
1Department of Urology, St.-Agnes-Hospital, Bocholt, Germany
2Strathmann AG & Co., Hamburg, Germany

Tài liệu tham khảo

Abrams, 1993, The objective evaluation of bladder outflow obstruction, 151

Ball, 1981, The natural history of untreated “prostatism”, Br. J. Urol., 53, 613, 10.1111/j.1464-410X.1981.tb03273.x

Barnes, 1983, Progression of obstruction and symptoms, 711

Birkhoff, 1976, Natural history of benign prostatic hypertrophy and acute urinary retention, Urology, 7, 48, 10.1016/0090-4295(76)90560-4

Boyarsky, 1977, A new look at bladder neck obstruction by the Food and Drug Administration regulators: Guidelines for investigation of benign prostate hypertrophy, Trans Am. Assoc. Genito-Urin. Surg., 68, 29

Craigen, 1969, Natural history of prostatic obstruction, J. Roy. Coll. Gebn. Practit., 18, 226

Fabricius, 1992, Placebo-controlled study of terazosin in the treatment of benign prostatic hyperplasia with 2-year follow-up, Br. J. Urol., 70, 10, 10.1111/j.1464-410X.1992.tb15861.x

Gormley, 1993, The effect of finasteride in men with benign prostatic hyperplasia, N. Engl. J. Med., 327, 1185, 10.1056/NEJM199210223271701

Helpap, 1995, Morphology of benign prostatic hyperplasia after treatment with Sabal extract IDS 89 or placebo, J. Urol. Pathol., 3, 175

1991, Recommendations concerning 1. Prostate Symptom Score (I-PSS) and Quality of life assessment, 279

Jardin, 1993, α-Blockers therapy in benign prostatic hyperplasia, 377

Lepor, 1994, The treatment of benign prostatic hyperplasia with alphaj blockers, Curr. Opinion Urol., 4, 16, 10.1097/00042307-199401000-00004

Lepor, 1991, The efficacy and safety of terazosin for the treatment of symptomatic BPH, Prostate, 18, 345, 10.1002/pros.2990180408

Lepor, 1991, The efficacy and safety of terazosin for the treatment of symptomatic BPH, Prostate, 18, 345, 10.1002/pros.2990180408

Lepor, 1992, The safety, efficacy and compliance of terazosin therapy for benign prostatic hyperplasia.J, Urol., 147, 1554, 10.1016/S0022-5347(17)37624-3

McConnell, 1993, Hormonal treatment of benign prostatic hyperplasia, 417

Monda, 1993, Medical treatment of benign prostatic hyperplasia: 5 α-reductase inhibitors and α-adrenergic antagonists, Mayo Clin. Proc., 68, 670, 10.1016/S0025-6196(12)60603-X

Nakajin, 1994, Purification of 3 α/β-hydroxysteroid dehydrogenase from mature porcine testicular cytosol, J. Steroid Biochem. Molec. Biol., 48, 249, 10.1016/0960-0760(94)90152-X

Romics, 1993, Experience in treating benign prostatic hypertrophy with Sabal serrulata for one year, Int. Urol. Nephrol., 25, 565

Schäfer, 1992, Urodynamik bei benigner Prostatahyperplasie, 134

Schulze, 1992, Neue konservative Therapieansätze bei der benignen Prostatahyperplasie, Urologe [A], 31, 8

Stoner, 1994, Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasy, Urology, 43, 284, 10.1016/0090-4295(94)90068-X

1993, Finasteride (MK-906) in the treatment of benign prostatic hyperplasia, Prostate, 22, 291, 10.1002/pros.2990220403

Tunn, 1992, 18

Weisser, H., Behnke, B., Helpap, B., Bach, D., Krieg, M.: Enzyme activities in tissue if human benign prostatic hyperplasia (BPH) after three months treatment with Sabal serrulata extract IDS 89 (Strogen) or placebo. Eur. Urol., in press.

Wilde, 1993, Terazosin. A review of its pharmacodynamic properties, and therapeutic potential in benign prostatic hyperplasia, Drug & Aging, 3, 258, 10.2165/00002512-199303030-00007

Thông tin
Thông tin xuất bản

Phytomedicine

Tập 3

105-111

Thông tin tác giả